For the year ending 2025-12-31, ESPR had $23,091K increase in cash & cash equivalents over the period. -$13,093K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -22,682 |
| Non-cash loss on extinguishment of debt and exchange transaction | 0 |
| Non-cash royalty revenue | 55,055 |
| Paid-in-kind interest on long-term debt | 9,093 |
| Non-cash interest expense related to the revenue interest liability | 0 |
| Non-cash interest expense related to the royalty sale liability | 57,211 |
| Stock-based compensation expense | 9,870 |
| Depreciation expense | 105 |
| Accretion and amortization of premiums and discounts on investments | 0 |
| Amortization of debt issuance costs and discounts | 3,007 |
| Accounts receivable | 60,048 |
| Prepaids and other assets | 30,800 |
| Deferred revenue | 25,959 |
| Inventories | 10,633 |
| Accounts payable | 20,918 |
| Other accrued liabilities | 31,223 |
| Other long-term liabilities | 8,739 |
| Net cash used in operating activities | -13,093 |
| Proceeds from sales/maturities of investments | 0 |
| Purchases of property and equipment | 0 |
| Net cash (used in) provided by investing activities | 0 |
| Proceeds from royalty sale liability | 0 |
| Payment of royalty sale liability issuance costs | 0 |
| Repurchase or principal payment of revenue interest liability | 0 |
| Payments on revenue interest liability | 0 |
| Proceeds from credit agreement, net of issuance costs | 0 |
| Proceeds from issuance of convertible notes, net of issuance costs | 0 |
| Repayment of convertible notes | 54,912 |
| Proceeds from issuance of common stock, net of issuance costs | 72,596 |
| Proceeds from issuance of common stock from atm program, net of issuance costs | 15,408 |
| Proceeds from exercise of warrants | 10,348 |
| Payment of issuance costs | 7,500 |
| Other financing activities | 244 |
| Net cash provided by financing activities | 36,184 |
| Net increase (decrease) in cash and cash equivalents | 23,091 |
| Cash, cash equivalents at beginning of period | 144,761 |
| Cash and cash equivalents at end of period | 167,852 |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)